CHPA appreciates the opportunity to provide information on features to add and potential functionality improvements to make the Dietary Supplement Label Database a more useful tool for regulators, consumers, and other users of the database.
CHPA appreciates the opportunity to provide information relevant to use of the term “natural” in food labeling, and believes that a formal definition will help to reduce consumer confusion and provide clarity to manufacturers and marketers making claims relying upon such a definition.
CHPA appreciates the opportunity to provide the National Osteoporosis Foundation with comments on their recently released "Position Statement on Calcium and Cardiovascular Disease" as well as the Evidence Report on which it is based.
We strongly agree that healthcare product manufacturers have a central role to play in the fight against this pandemic. Provided employers comply with CDC guidelines to protect workers, healthcare product manufacturers have the special responsibility to maintain their current work schedules.
In order to ensure the continued safe reporting of adverse events associated with our member's products and prevent consumer confusion, we strongly believe OTC and dietary supplement product incident reports should not be included in the CPSC safety incident database.
We would like to add our voice to the American Herbal Products Association, the Council for Responsible Nutrition, and the National Nutrition Foods Association in supporting the joint industry submission.
These comments are submitted on behalf of CRN and CHPA in response to the FDA Notice and Request for Comments on the implementation of section 301(ll) of the Federal Food, Drug, and Cosmetic Act.
CRN, CHPA, and their member companies are concerned with and offer the following comments to the proposed revisions to the USP-NF General Chapter <467> on Residual Solvents.
